You just read:

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

News provided by

Ionis Pharmaceuticals, Inc.

Jul 05, 2018, 07:00 ET